



For immediate release

04 May 2011

Zilico announces the completion of patient recruitment

Zilico announced that it has completed recruitment into its European multi-centre trial. This trial is designed to demonstrate the performance of its portable diagnostic device within a cervical cancer screening programme. The device is positioned as an adjunct to colposcopy to help accurately identify sites for biopsy. The trial has been carried out at three centres with international reputations in colposcopy and cervical cancer.

A total of over 400 women have now been recruited into the trial, which meets the requirements of the protocol agreed with the appropriate regulatory bodies and research ethics committees. The structure of the trial is such that Zilico expects to collect all the data and complete the analysis by June 2011.

Analysis of the early data from this trial has been encouraging and has demonstrated that the current, pre-production version of the device improves on the performance of earlier prototypes. These prototypes were used in four earlier trials on a total of over 500 women to demonstrate the applicability of EIS technology to the detection of cervical pre-cancer and cancer. The data from all these studies have been published in peer-reviewed journals.

Zilico will use the data from this trial to obtain a CE Mark for the use of the device as an adjunct to colposcopy and expects to launch the product by the end of 2011.

For more information please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: sameer.kothari@zilico.co.uk

Notes for editors:

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy (EIS), an objective scientifically-proven method to differentiate between normal, pre-cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico (previously known as Aperio Diagnostic Ltd) has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.